Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per Share

Wall Street analysts expect that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will post earnings per share of ($0.25) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sunesis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.33). Sunesis Pharmaceuticals posted earnings per share of ($0.44) in the same quarter last year, which indicates a positive year over year growth rate of 43.2%. The company is scheduled to report its next quarterly earnings report on Thursday, March 8th.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.48). For the next financial year, analysts expect that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same quarter last year, the company earned ($0.62) EPS.

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. UBS Group assumed coverage on shares of Sunesis Pharmaceuticals in a research note on Monday, November 20th. They set an “outperform” rating for the company. Oppenheimer assumed coverage on shares of Sunesis Pharmaceuticals in a research note on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target for the company. Wells Fargo & Co raised shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price target for the company from $2.86 to $2.48 in a research note on Monday, December 11th. Finally, Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.75.

In other news, Director Dayton Misfeldt acquired 400,000 shares of the firm’s stock in a transaction dated Friday, October 27th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $800,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were purchased at an average price of $2.59 per share, with a total value of $65,527.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN increased its position in shares of Sunesis Pharmaceuticals by 127.6% during the third quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 53,396 shares during the period. Balyasny Asset Management LLC acquired a new stake in shares of Sunesis Pharmaceuticals during the second quarter worth $5,400,000. Virtu KCG Holdings LLC acquired a new stake in shares of Sunesis Pharmaceuticals during the second quarter worth $208,000. Vanguard Group Inc. increased its position in shares of Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 23,819 shares during the period. Finally, Sphera Funds Management LTD. increased its position in shares of Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 68,212 shares during the period. Institutional investors own 38.21% of the company’s stock.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up $0.05 during trading hours on Tuesday, reaching $3.35. 62,900 shares of the company traded hands, compared to its average volume of 132,293. The company has a market cap of $115.07, a P/E ratio of -1.91 and a beta of 1.55. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84. Sunesis Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $4.45.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per Share” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://weekherald.com/2017/12/26/zacks-brokerages-expect-sunesis-pharmaceuticals-inc-snss-will-post-earnings-of-0-25-per-share.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply